Comparative Pharmacology
Head-to-head clinical analysis: CAMOQUIN HYDROCHLORIDE versus LARIAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAMOQUIN HYDROCHLORIDE versus LARIAM.
CAMOQUIN HYDROCHLORIDE vs LARIAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amodiaquine hydrochloride is a 4-aminoquinoline compound that acts as a blood schizonticide. It inhibits heme polymerase, leading to accumulation of toxic heme-iron complexes in the parasite's food vacuole, disrupting membrane function and parasite replication.
Mefloquine is a 4-quinolinemethanol antimalarial agent that acts as a blood schizontocide. Its exact mechanism is unknown, but it is thought to inhibit heme polymerase, leading to toxic accumulation of free heme in the parasite.
600 mg base (1 g salt) orally once weekly for prophylaxis; 600 mg base (1 g salt) initially followed by 600 mg base at 6, 24, and 48 hours for treatment of malaria.
For malaria prophylaxis: 250 mg (base) orally once weekly starting 1-2 weeks before travel, continuing weekly during stay and for 4 weeks after leaving endemic area. For malaria treatment: 1250 mg (base) orally as a single dose, divided if needed (750 mg followed by 500 mg after 6-12 hours). Route: oral. Frequency: weekly for prophylaxis; single dose for treatment.
None Documented
None Documented
Terminal elimination half-life ranges 9–21 days (mean ~14 days) due to extensive tissue binding; clinical context: steady-state achieved after 4–6 weeks, prolonged half-life allows weekly dosing for malaria prophylaxis.
Terminal elimination half-life: approximately 3 weeks (range 13–33 days); prolonged due to extensive tissue distribution and slow release from erythrocytes.
Primarily hepatic metabolism (approx. 60-70%) with metabolites excreted in bile and feces; renal excretion of unchanged drug accounts for <5% of the dose. Fecal elimination accounts for ~20-30% of the dose, with minor biliary contribution.
Hepatic metabolism (primarily CYP3A4) followed by biliary/fecal elimination; ~40% unchanged in feces, ~9% as metabolites in urine, minimal renal excretion of parent drug (<5%).
Category C
Category C
Antimalarial
Antimalarial